Role of influenza vaccine for healthy children in the US

Pediatric Drugs

Volumn 6, Issue 4, 2004, Pages 199-209

  Block, Stan L ^a  

^a Kentucky Pediatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLD ADAPTED INFLUENZA VIRUS VACCINE; INFLUENZA VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG;

CHILD; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEVER; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTITIONER; HEADACHE; HEALTH CARE MANAGEMENT; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; LOGISTIC REGRESSION ANALYSIS; MORBIDITY; MORTALITY; MYALGIA; PASSIVE IMMUNIZATION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RHINORRHEA; SEROLOGY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UNITED STATES; VIRUS INACTIVATION; VIRUS RECOMBINATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; UNITED STATES;

EID: 6044261515     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200406040-00001     Document Type: Review

References (76)

1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2001; 50 (RR-4): 1-44
2. Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996; 9 Suppl. 3: 26-33
3. Barnett ED. Influenza immunization for children. N Engl J Med 1998; 338: 1459-61
4. Szucs TD. Influenza: the role of burden-of-illness research. Pharmacoeconomics 1999; 16 Suppl. 1: 27-32
5. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002; 51 (RR-3): 1-34
6. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996; 18: 64-76
7. Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol Infect 1993; 110; 145-60
8. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342: 225-31
9. Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev Infect Dis 1980; 2; 408-20
10. Centers for Disease Control and Prevention. Severe morbidity and mortality associated with influenza in children and young adults: Michigan, 2003. MMWR Morb Mortal Wkly Rep 2003; 52 (35): 837-40
11. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86
12. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000; 342: 232-9
13. Quach C, Piché-Walker L, Platt R, et al. Risk factors associated with severe influenza infections in childhood: implications for vaccine strategy. Pediatrics 2003; 112: el97-201
14. Glezen WP. Influenza vaccination for healthy children. Curr Opin Infect Dis 2002; 15: 283-7
15. Glezen WP. Influenza viruses. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Philadelphia (PA): WB Saunders Company, 1998: 2024-40
16. Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21: 273-83
17. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354: 1277-82
18. Poland GA, Hall CB. Influenza immunization of schoolchildren: can we interrupt the epidemic? Pediatrics 1999; 103: 1280-2
19. Dawson DA, Cain VS. Childcare arrangements: health of our nation's children: United States, 1988. Adv Data 1990; 187: 1-12
20. Fleming DW, Cochi SL, Hightower AW, et al. Childhood upper respiratory tract infections: to what degree is incidence affected by day-care attendance? Pediatrics 1987; 79: 55-60
21. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000; 284: 1677-82
22. Heilman C, La Montagne JR. Influenza: status and prospects for its prevention, therapy, and control. Pediatr Clin North Am 1990; 37: 669-88
23. Plotkin SA, Orenstein WA. Inactivated influenza vaccines. In: Vaccine. 3rd ed. Philadelphia (PA): WB Saunders Company, 1999: 59
24. Jacobson RM, Poland GA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Paediatr Drugs 2002; 4: 65-71
25. Neuzil KM, Dupont WD, Wright PF, et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001; 20: 733-40
26. Gonzalez M, Pirez MC, Ward E, et al. Safety and immunogenicity of a pediatric presentation of an influenza vaccine. Arch Dis Child 2000; 83: 488-91
27. Heikkinen T, Ruuskanen O, Waris M, et al. Influenza vaccination in the prevention of acute otitis media. Am J Dis Child 1991; 145: 445-8
28. Clements DA, Langdon L, Bland C, et al. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149: 1113-7
29. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children, a randomized controlled trial. JAMA 2003; 290: 1608-16
30. Znagwill KM, Belshe RB. Safety and efficacy or trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J 2004; 23: 189-200
31. Gruber WC, Taber LH, Glezen WP, et al. Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 1990; 144: 595-600
32. Clover RD, Crawford S, Glezen WP. et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 1991; 163: 300-4
33. Piedra PA, Glezen WP. Influenza in children: epidemiology, immunity, and vaccines. Semin Pediatr Infect Dis 1991; 2: 140-6
34. Hurwitz ES, Haber M, Chang A. et al. Studies of the 1996-7 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 2000; 182: 1218-21
35. Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169: 68-76
36. Fairchok MP, Trementozzi DP, Carter PS, et al. Effect of prednisone on response to influenza virus vaccine in asthmatic children. Arch Pediatr Adolesc Med 1998; 152: 1191-5
37. Kramarz P, DeStefano F, Gargiullo PM, et al. Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Arch Fam Med 2000; 9: 617-3
38. Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother 2000; 54: 210-8
39. Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 1999; 9: 237-4
40. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000; 106: 973-6
41. Centers for Disease Control and Prevention. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52 (RR-13): 1-8
42. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136: 168-75
43. Johnson PR, Feldman S, Thompson JM, et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986; 154: 121-7
44. Block SL. New data on influenza vaccines in children [letter]. Pediatr Infect Dis J 2004; 23: 85
45. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23: 66-72
46. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133-7
47. Gorse GJ, Campbell MJ, Otto EE, et al. Increased anti-influenza A virus cytotoxic T-cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 1995; 172: 1-10
48. Tomoda T, Morita H, Kurashige T, et al. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza vaccine: importance of interferon gamma production and local IgA response. Vaccine 1995; 13: 185-90
49. McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309: 13-7
50. Wright PF, Johnson PR, Karzon DT. Clinical experience with live, attenuated vaccines in children in options for the control of influenza. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza. Proceedings of a Viratek-UCLA Symposium; 1985 Apr 20-25: Keystone. New York (NY): Alan R. Liss, 1986: 243-53
51. Johnson PR, Feldman S, Thompson JM, et al. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 1985; 17: 325-35
52. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998; 338: 1405-12
53. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated, intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282: 137-44
54. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284: 1655-63
55. Halloran ME, Longini IM, Gaglani MJ, et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 2003; 158: 305-11
56. Mendelman PM, Cordova J, Cho I. Safety, efficacy, and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 2001; 19: 2221-6
57. Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002; 21: 44-8
58. Gruber WC, Campbell PW, Thompson JM, et al. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J Infect Dis 1994; 169: 241-7
59. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23: 138-44
60. Wyeth Vaccines. FluMist™ [package insert]. Philadelphia (PA): Wyeth Vaccines, 2003
61. Data on file, MedImmune Vaccines Inc., 2003
62. Murphy BR, Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002; 15: 295-323
63. Subbarao K. As good as the real thing. J Pediatr 2000; 136: 139-41
64. Keitel WA, Piedra PA. Live cold-adapted, reassortant influenza vaccines (USA). In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 373-90
65. Vesikari T, Aristegui JF, Ashkenazi S, et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending day care. Presented at the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago
66. Ashkenazi S, Vertruyen A, Aristegui J, et al. Comparison of safety and efficacy of a trivalent live attenuated intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children aged 6 to <72 months with a history of respiratory tract infections [late breaker abstract no. 7]. Pediatric Academic Societies' Annual Meeting; 2004 May 1-4; San Francisco
67. Wahn U, Crovari P, Fleming D, et al. Comparison of safety and efficacy of a trivalent live attenuated intranasal influenza vaccine (CAIV-T) with trivalent inactivated intramuscular influenza vaccine (TIV) in children and adolescents aged 6 to <18 years with asthma [late breaker abstract no. 20]. Pediatric Academic Societies' Annual Meeting; 2004 May 1-4; San Francisco
68. Karron RA, Steinhoff MC, Subbarao EK, et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995; 14: 10-6
69. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for influenza immunization of children. Pediatrics 2004 May; 113 (5): 1441-7
70. Szilagyi PG, Iwane MK, Schaffer S, et al. Potential burden of universal influenza vaccination of young children on visits to primary care practices. Pediatrics 2003; 112: 821-8
71. Monto AS, Davenport FM, Napier JA, et al. Effect of vaccination of a school-age population upon the course of an A2/Hong Kong influenza epidemic. Bull World Health Organ 1969; 41: 537-42
72. Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344: 889-96
73. Nichol KL. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84
74. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161: 749-59
75. White T, Lavoie S, Nettleman M. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999; 103: e73
76. Luce BR, Zangwill KM, Palmer SC, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108: e24